Products
Zemocimig Biosimilar Bispecific Antibody (Factor IXa × Factor X) for Research
Cat No.: GMP-Bios-INN-1473
Anti-F9a therapeutic antibody (Pre-made Zemocimig biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Zemocimig (development codes NXT007/RG6512) is a humanized bispecific monoclonal antibody targeting F9a and coagulation factor X (F10). It is developed by Hoffmann-La Roche for Hemophilia A in Phase III development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1473-1mg | 1mg | |
| GMP-Bios-INN-1473-10mg | 10mg | |
| GMP-Bios-INN-1473-100mg | 100mg | |
| GMP-Bios-INN-1473-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Zemocimig biosimilar, Bispecific mAb, Anti-F9a;F10 Antibody: Anti-Factor X/F10/Coagulation factor X/Stuart factor therapeutic antibody |
| INN Name | Zemocimig |
| Target | F9a;F10 |
| Format | Bispecific mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4;G4 |
| VD LC | Kappa;Lambda |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | TBC |
| 100% SI Structure | 8gv0:AB:CD:EF:GH/8guz:AB:CD;8gv1:AB/8gv2:AB |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2025 |
| Year Recommended | na |
| Companies | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Production | na |
| Development Tech | TBC |
